Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Placon Therapeutics, Inc.

Tarveda Therapeutics, Inc.

Tva (abc), LLC

Sumitomo Dainippon Pharma Co., Ltd.

Mark T Bilodeau

Peter J Manley

Benoît Moreau

Richard Wooster

Rossitza Gueorguieva Alargova

Rajesh R Shinde

Zhicai Wu

Randall W Hungate

B Wesley Trotter

George D Hartman

Mark E Fraley

Sudhakar Kadiyala

Craig Antony Dunbar

Patrick Lim Soo

John C Hartnett

Jacob M Hoffman

Adam H Brockman

Edward R Lee

Nicholas D P Cosford

Kausik K Nanda

Brian H White

Kerry Whalen

Beata Sweryda-Krawiec

Patrick Rosaire Bazinet

Lou Anne Neilson

Yiwei Li

Craig William Lindsley

Zhijian Zhao

M Brad Nolt

Timothy E Barder

Danielle N Rockwood

Leonard Rodman

Mark E Duggan

William F Hoffman

Christopher J Dinsmore

Yuntae Kim

Jun Liang

Robert S Rubino

Johnny Yasuo Nagasawa

Lida R Tehrani

Tony Siu

Jeffrey M Bergman

Kenneth L Arrington

Scott E Wolkenberg

Essa H Hu

Richard L Kendall

Kristan Meetze

Kenneth A Thomas

Nathan R Kett

Peter C Chua

Ahren Iver Green

Adrienne E Balitza

Timothy J Koester

April M Cunningham

Ruth Rutledge

David A Claremon

Nigel J Liverton

John M Sanders

Matthew G Stanton

Michael D Altman

Melissa S Egbertson

John A McCauley

J Michael Ramstack

James C Barrow

Jongwon Lim

Christopher D Cox

Brian Andrew Stearns

Alan B Northrup

Thomas Joseph Tucker

Douglas C Beshore

Brian Walter Eastman

Mark E Layton

Thomas J Greshock

Jeannie M Arruda

John W Butcher

Brian T Campbell

Linda S Payne

William D Shipe

Brandon Mitsuo Taoka

Matthew Mangzhu Zhao

Chixu Chen

Hemaka Anthony Rajapakse

Richard C Isaacs

John T Sisko

Anthony M Smith

Kevin J Rodzinak

Vanessa L Rada

Boyoung Kim

William C Lumma

Heather E Stevenson

Amy Zartman

Richard C A Isaacs

Samantha Perino

Jeffrey Melamed

Jonathan T Kern

Wesley B Trotter

Leila Alland

Sukhjeet Singh

Tsun P Au Yeung

Linda M Custer

Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.

HSP90 targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Targeted conjugates and particles and formulations thereof

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

HSP90-targeting conjugates and formulations thereof

Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

SSTR-targeted conjugates and particles and formulations thereof

The present disclosure relates to novel platinum compositions having a heterocycle ligand and nanoparticles and methods using such compositions, e.g. for treating cancer.

Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.

Platinum compounds, compositions, and uses thereof

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.

Compounds, compositions, and methods for the treatment of cancers

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.

The present invention is directed to therapeutic agents which are atypical antipsychotics and which are useful in the treatment of neurological and psychiatric disorders associated with dopamine D2 and serotonin 5-HT2A neurotransmission dysfunction.

Hexahydro-1H-4,7-methanoisoindole-1,3-dione compounds

Growing community of inventors

Lansdale, PA, United States of America

Mark T Bilodeau